Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania

Malar J. 2016 Jun 23:15:335. doi: 10.1186/s12936-016-1387-2.

Abstract

Background: Sulfadoxine-pyrimethamine (SP) is recommended for prophylactic treatment of malaria in pregnancy while artemisinin combination therapy is the recommended first-line anti-malarial treatment. Selection of SP resistance is ongoing since SP is readily available in health facilities and in private drug shops in sub-Saharan Africa. This study reports on the prevalence and distribution of Pfdhps mutations A540E and A581G in Tanzania. When found together, these mutations confer high-level SP resistance (sometimes referred to as 'super-resistance'), which is associated with loss in protective efficacy of SP-IPTp.

Methods: DNA samples were extracted from malaria-positive blood samples on filter paper, used malaria rapid diagnostic test strips and whole blood collected from eight sites in seven administrative regions of Tanzania. PCR-RFLP and SSOP-ELISA techniques were used to genotype the A540E and A581G Pfdhps. Data were analysed using SPSS version 18 while Chi square and/or Fischer Exact tests were used to compare prevalence between regions.

Results: A high inter-regional variation of Pfdhps-540E was observed (χ(2) = 76.8, p < 0.001). High inter-regional variation of 581G was observed (FE = 85.3, p < 0.001). Both Tanga and Kagera were found to have the highest levels of SP resistance. A high prevalence of Pfdhps-581G was observed in Tanga (56.6 %) in northeastern Tanzania and in Kagera (20.4 %) in northwestern Tanzania and the 540-581 EG haplotype was found at 54.5 and 19.4 %, respectively. Pfdhps-581G was not detected in Pwani and Lindi regions located south of Tanga region.

Conclusions: Selection of SP super-resistant Pfdhps A581G is highest in northern Tanzania. Variation in distribution of SP resistance is observed across the country: northeastern Tanga region and northwestern Kagera region have highest prevalence of SP super-resistance markers, while in Pwani and Lindi in the southeast the prevalence of super-resistance was zero. More studies should be conducted to understand the factors underlying the remarkable heterogeneity in SP resistance in the country.

Keywords: Anti-malarial drugs; Drug resistance; Malaria; Mutations; Parasites; Plasmodium falciparum; Polymorphisms; SP-resistance; SP-super resistance; Sulfadoxine-pyrimethamine; Tanzania.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / pharmacology*
  • DNA, Protozoan / genetics
  • DNA, Protozoan / isolation & purification
  • Dihydropteroate Synthase / genetics*
  • Drug Combinations
  • Drug Resistance*
  • Gene Frequency
  • Genotyping Techniques
  • Humans
  • Malaria, Falciparum / parasitology
  • Mutation, Missense
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / enzymology*
  • Plasmodium falciparum / genetics
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Pyrimethamine / pharmacology*
  • Sulfadoxine / pharmacology*
  • Tanzania

Substances

  • Antimalarials
  • DNA, Protozoan
  • Drug Combinations
  • fanasil, pyrimethamine drug combination
  • Sulfadoxine
  • Dihydropteroate Synthase
  • Pyrimethamine